Venkatakrishnan K - Search Results

1

Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses.

Gupta N, Yang H, Hanley MJ, Zhang S, Liu R, Kumar S, Richardson PG, Skacel T, Venkatakrishnan K. Gupta N, et al. Among authors: venkatakrishnan k. Target Oncol. 2017 Oct;12(5):643-654. doi: 10.1007/s11523-017-0524-3. Target Oncol. 2017. PMID: 28803351 Free PMC article. Clinical Trial.

2

Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis.

Gupta N, Zhao Y, Hui AM, Esseltine DL, Venkatakrishnan K. Gupta N, et al. Among authors: venkatakrishnan k. Br J Clin Pharmacol. 2015 May;79(5):789-800. doi: 10.1111/bcp.12542. Br J Clin Pharmacol. 2015. PMID: 25377318 Free PMC article.

3

Integrated nonclinical and clinical risk assessment of the investigational proteasome inhibitor ixazomib on the QTc interval in cancer patients.

Gupta N, Huh Y, Hutmacher MM, Ottinger S, Hui AM, Venkatakrishnan K. Gupta N, et al. Among authors: venkatakrishnan k. Cancer Chemother Pharmacol. 2015 Sep;76(3):507-16. doi: 10.1007/s00280-015-2815-7. Epub 2015 Jul 4. Cancer Chemother Pharmacol. 2015. PMID: 26141494

4

Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study.

Gupta N, Goh YT, Min CK, Lee JH, Kim K, Wong RS, Chim CS, Hanley MJ, Yang H, Venkatakrishnan K, Hui AM, Esseltine DL, Chng WJ. Gupta N, et al. Among authors: venkatakrishnan k. J Hematol Oncol. 2015 Sep 4;8:103. doi: 10.1186/s13045-015-0198-1. J Hematol Oncol. 2015. PMID: 26337806 Free PMC article. Clinical Trial.

5

Toward Optimum Benefit-Risk and Reduced Access Lag For Cancer Drugs in Asia: A Global Development Framework Guided by Clinical Pharmacology Principles.

Venkatakrishnan K, Burgess C, Gupta N, Suri A, Takubo T, Zhou X, DeMuria D, Lehnert M, Takeyama K, Singhvi S, Milton A. Venkatakrishnan K, et al. Clin Transl Sci. 2016 Feb;9(1):9-22. doi: 10.1111/cts.12386. Epub 2016 Feb 5. Clin Transl Sci. 2016. PMID: 26836226 Free PMC article. Review. No abstract available.

6

The Effect of a High-Fat Meal on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma.

Gupta N, Hanley MJ, Venkatakrishnan K, Wang B, Sharma S, Bessudo A, Hui AM, Nemunaitis J. Gupta N, et al. Among authors: venkatakrishnan k. J Clin Pharmacol. 2016 Oct;56(10):1288-95. doi: 10.1002/jcph.719. Epub 2016 Mar 17. J Clin Pharmacol. 2016. PMID: 26872892 Free PMC article. Clinical Trial.

7

Exposure-safety-efficacy analysis of single-agent ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma: dose selection for a phase 3 maintenance study.

Gupta N, Labotka R, Liu G, Hui AM, Venkatakrishnan K. Gupta N, et al. Among authors: venkatakrishnan k. Invest New Drugs. 2016 Jun;34(3):338-46. doi: 10.1007/s10637-016-0346-7. Epub 2016 Apr 2. Invest New Drugs. 2016. PMID: 27039387 Free PMC article. Clinical Trial.

8

Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment.

Gupta N, Hanley MJ, Venkatakrishnan K, Perez R, Norris RE, Nemunaitis J, Yang H, Qian MG, Falchook G, Labotka R, Fu S. Gupta N, et al. Among authors: venkatakrishnan k. Br J Clin Pharmacol. 2016 Sep;82(3):728-38. doi: 10.1111/bcp.12991. Epub 2016 May 29. Br J Clin Pharmacol. 2016. PMID: 27121262 Free PMC article. Clinical Trial.

9

A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-stage renal disease requiring haemodialysis.

Gupta N, Hanley MJ, Harvey RD, Badros A, Lipe B, Kukreti V, Berdeja J, Yang H, Hui AM, Qian M, Zhang X, Venkatakrishnan K, Chari A. Gupta N, et al. Among authors: venkatakrishnan k. Br J Haematol. 2016 Sep;174(5):748-59. doi: 10.1111/bjh.14125. Epub 2016 May 16. Br J Haematol. 2016. PMID: 27196567 Free PMC article. Clinical Trial.

10

Population Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform Labelling.

Gupta N, Diderichsen PM, Hanley MJ, Berg D, van de Velde H, Harvey RD, Venkatakrishnan K. Gupta N, et al. Among authors: venkatakrishnan k. Clin Pharmacokinet. 2017 Nov;56(11):1355-1368. doi: 10.1007/s40262-017-0526-4. Clin Pharmacokinet. 2017. PMID: 28290121 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

311 results

Search Page

Filters